Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs

Journal of Infectious Diseases

Volumn 204, Issue SUPPL. 3, 2011, Pages

  Richardson, Jason S ^a   Abou, Max C ^a   Tran, Kaylie N ^a   Kumar, Anand ^b   Sahai, Beni M ^c   Kobinger, Gary P ^a,b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c CADHAM PROVINCIAL LABORATORY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EBOLA VACCINE; VIRUS GLYCOPROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; EBOLA VIRUS INFECTION; GUINEA PIG; HUMORAL IMMUNITY; IMMUNITY; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMIC IMMUNITY; VACCINATION; VIRUS INFECTION; VIRUS STRAIN; ZAIRE EBOLAVIRUS;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; B-LYMPHOCYTES; BRONCHOALVEOLAR LAVAGE FLUID; EBOLA VACCINES; GLYCOPROTEINS; GUINEA PIGS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INJECTIONS, INTRAMUSCULAR; NASAL MUCOSA; VACCINES, SYNTHETIC;

EID: 80054737077     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir332     Document Type: Conference Paper

References (50)

1. Wilson JA, Bosio CM, Hart MK. Ebola virus: the search for vaccines and treatments. Cell Mol Life Sci 2001; 58:1826-41. (Pubitemid 33108772)
2. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002; 287:2391-405. (Pubitemid 34493202)
3. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23:3033-42. (Pubitemid 40462443)
4. Warfield KL, Bosio CM, Welcher BC, et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A2003; 100:15889-94. (Pubitemid 38021085)
5. Warfield KL, Olinger G, Deal EM, et al. Induction of humoral and CD81 T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005; 175:1184-91. (Pubitemid 41095006)
6. Warfield KL, Swenson DL, Olinger GG, KalinaWV, Aman MJ, Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007; 196(Suppl 2):S430-7. (Pubitemid 351417291)
7. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLoS Pathog 2007; 3:e2.
8. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replicationcompetent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65. (Pubitemid 38581495)
9. Geisbert TW, Geisbert JB, Leung A, et al. Single-injection vaccine protects nonhuman primates against infection with Marburg virus and three species of Ebola virus. J Virol 2009; 83:7296-304.
10. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90. (Pubitemid 41021212)
11. Qiu X, Fernando L, Alimonti JB, et al. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 2009; 4:e5547.
12. Bukreyev A, Rollin PE, Tate MK, et al. Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 2007; 81: 6379-88. (Pubitemid 46878044)
13. Bukreyev A, Yang L, Zaki SR, et al. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethaldose Ebola virus challenge. J Virol 2006; 80:2267-79. (Pubitemid 43271533)
14. Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 2008; 377:255-64. (Pubitemid 351822376)
15. Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirusbased vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:e3548.
16. Patel A, Zhang Y, Croyle M, et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 2007; 196(Suppl 2):S413-20. (Pubitemid 351417289)
17. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 2009; 4:e5308.
18. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 2006; 3:e177.
19. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408:605-9.
20. Nazir SA, Metcalf JP. Innate immune response to adenovirus. J Investig Med 2005; 53:292-304. (Pubitemid 41527768)
21. Boyer JL, Kobinger G, Wilson JM, Crystal RG. Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 2005; 16:157-68. (Pubitemid 40344208)
22. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255-66. (Pubitemid 46613525)
23. Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006; 13:1267-77. (Pubitemid 46768881)
24. Abbink P, Lemckert AA, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007; 81:4654-63. (Pubitemid 46668663)
25. Nwanegbo E, Vardas E, Gao W, et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of the Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11:351-7. (Pubitemid 38380817)
26. Gallo P, Dharmapuri S, Cipriani B, Monaci P. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 2005; 12(Suppl 1): S84-91. (Pubitemid 41541756)
27. Nanda A, Lynch DM, Goudsmit J, et al. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys. J Virol 2005; 79:14161-8. (Pubitemid 41552714)
28. Capone S, Meola A, Ercole BB, et al. A novel adenovirus type 6 (Ad6)- based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J Virol 2006; 80:1688-99. (Pubitemid 43228711)
29. Kobinger GP, Feldmann H, Zhi Y, et al. Chimpanzee adenovirus vaccine protects against Zaire ebola virus. Virology 2006; 346: 394-401. (Pubitemid 43357883)
30. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of preexisting immunity against human adenovirus. Mol Ther 2008; 16:965-71. (Pubitemid 351587108)
31. O'Riordan CR, Lachapelle A, Delgado C, et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10:1349-58. (Pubitemid 29267589)
32. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1- deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 2002; 13:1887-900. (Pubitemid 35292683)
33. Croyle MA, Le HT, Linse KD, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005; 12:579-87. (Pubitemid 40468105)
34. Eto Y, Gao JQ, Sekiguchi F, et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 2005; 7:604-12. (Pubitemid 40744526)
35. Arvin AM, Greenberg HB. New viral vaccines. Virology 2006; 344:240-9. (Pubitemid 41818951)
36. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003; 170:5636-43. (Pubitemid 36617855)
37. Lajeunesse M, Zhang Q, Finn A. Mucosal immunity to infections and its importance in future vaccinology. Adv Exp Med Biol 2004; 549:13-22. (Pubitemid 38968175)
38. Basset C, Holton J, O'Mahony R, Roitt I. Innate immunity and pathogen- host interaction. Vaccine 2003; 21(Suppl 2):S12-23. (Pubitemid 36588646)
39. Zhou D, ErtlHC. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin Biol Ther 2006; 6:63-72. (Pubitemid 43049347)
40. Sullivan NJ, Geisbert TW, Geisbert JB, et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003; 424:681-4. (Pubitemid 36987993)
41. Connolly BM, Steele KE, Davis KJ, et al. Pathogenesis of experimental Ebola virus infection in guinea pigs. J Infect Dis 1999; 179(Suppl 1): S203-17. (Pubitemid 29091404)
42. Hoenen T, Groseth A, Kolesnikova L, et al. Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J Virol 2006; 80:7260-4. (Pubitemid 44025222)
43. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for the detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
44. Mohamadzadeh M, Chen L, Schmaljohn AL. How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 2007; 7: 556-67. (Pubitemid 46987780)
45. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004; 4:699-710. (Pubitemid 39223076)
46. Lefrancois L, Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 2006; 24:681-704.
47. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003; 77:10780-9. (Pubitemid 37204271)
48. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 2005; 73:6885-91. (Pubitemid 41368857)
49. Santosuosso M, McCormick S, Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 2005; 18:283-91. (Pubitemid 41106007)
50. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 2006; 14:662-72.S1042 d (Pubitemid 44480754)